Compare EQIX & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EQIX | GSK |
|---|---|---|
| Founded | 1998 | 1715 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.2B | 108.7B |
| IPO Year | 2000 | 2013 |
| Metric | EQIX | GSK |
|---|---|---|
| Price | $1,072.10 | $52.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 24 | 2 |
| Target Price | ★ $1,076.87 | N/A |
| AVG Volume (30 Days) | 536.4K | ★ 3.8M |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | 1.90% | ★ 3.40% |
| EPS Growth | ★ 61.88 | N/A |
| EPS | ★ 9.04 | N/A |
| Revenue | ★ $5,998,545,000.00 | N/A |
| Revenue This Year | $12.35 | $6.99 |
| Revenue Next Year | $8.88 | $4.19 |
| P/E Ratio | $116.73 | ★ $32.75 |
| Revenue Growth | ★ 7.85 | N/A |
| 52 Week Low | $720.62 | $38.63 |
| 52 Week High | $1,128.68 | $61.70 |
| Indicator | EQIX | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 50.32 | 50.33 |
| Support Level | $1,042.67 | $51.55 |
| Resistance Level | $1,108.60 | $51.79 |
| Average True Range (ATR) | 27.07 | 0.78 |
| MACD | -0.56 | 0.10 |
| Stochastic Oscillator | 39.44 | 66.98 |
Equinix is one of the leading providers of cloud- and carrier-neutral data centers, offering colocation and interconnection services to hyperscalers and businesses. Equinix operates 270 properties in 77 metropolitan areas across 36 countries, serving over 10,000 customers. About 70% of Equinix's revenue comes from renting physical space, which allows hyperscalers and other clients to store servers, data storage, and networking equipment. The other 30% of revenue is generated primarily through interconnection services (20%) and other managed services (10%).
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.